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ABSTRACT  
Oral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin. 
Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thro mbotic events 
associated to oral contraceptive use, we developed the present study.     
Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex, 
combination consumed, doses, co-morbidities, thrombotic events. 
Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel, 
gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (either 
depth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generation 
options). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins when 
compared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones.  
Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestin 
denote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies that 
provide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning. 
However, the combinations provided should not expose population to additional and unnecessary risks.  
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Oral contraceptive pills are the most popular birth control 
method worldwide used among reproductive-aged women1. 
For its proven efficacy to avoid ovulation and birth-rate the 
preferred option by prescribers, with the exception of 
breastfeeding period, is the combined oral contraceptive pill 
containing estrogens and progestogen compounds (CEPCs)2.  
Despite its reliable contraception action, this type of pills 
may present side-effects that include sodium and water 
retention, hirsute, headaches and/or venous thrombosis3. 
Although this last side-effect is infrequent (only 1–5 events 
per 10,000 women-years), it constitutes a dangerous adverse 
effect due to its serious consequences on health, which 
sometimes even involve putting women's lives at risk. 
However, different combination pills show different vessel 
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clotting obstruction tendencies, and thereby, dissimilar 
venous thrombosis risk. Even though the risk estrogens 
(usually ethinyl-oestradiol –EE-) dose (>30 ug) has a harmful 
effect on coagulation, the progestin component is actually the 
key point to differentiate the probability of suffering this 
serious adverse effect. 
Several studies have indicated that low-dose CEPCs, 
containing a combination of 30 µg EE and 150 µg 
desogestrel, had a higher risk of venous thromboembolism 
(VTE) than those containing 30 µg EE and 150 µg 
levonorgestrel4-8. Given that desogestrel, and newer 
progestogen generation -like gestodene, drosperinone or 
cyproterone per se, administered as progestin-only 
contraceptive- does not show any procoagulant effect and 
does not increase the risk of suffering VTE9, the increasing of 
the risk of VTE between EE-desogestrel vs EE-levonorgestrel 
can only be attributed to a different modulation of the pro-
coagulatory effect of EE, exerted by the two type of 
generation progestins10-14.  
Indeed, progestins may counteract the procoagulant effects 
of estrogen to varying degrees. Many studies4,15,16 indicated 
that progestogens with a high androgenic potency, 
antagonize the risk of VTE associated with EE more than 
newer progestins6-8. For this reason, contraceptives 
containing EE associated with “nor” compound 
(levonorgestrel, norgestrel or norgestimate) record a 
threefold increase in the risk for a VTE event2,17, which rises 
to a sixfold increase when the contraceptive contains 
desogestrel, gestodene, drospirenone, or cyproterone 
acetate2,6,7. Hence, it could be said that the new progestogen 
generation duplicates the risk of thrombosis in relation to 
old progestogen generation, like norgestrel or levonorgestrel 
when combine with EE. 
We can stand then, that while all combined monophasic oral 
contraceptive pills have the same effectiveness on 
preventing unwanted pregnancies, a group of them 
containing new progestogen generation compounds 
increases significantly thrombosis and thromboembolism 
risk. 
Knowing this fact, we conducted a research study to 
determine the type of contraceptives prescribed and 
financed by the Social Security of the State of Buenos Aires, 
and the thromboembolic events related to these medicines 
PATIENTS AND METHODS 
Type of Study: This is an observational-analytical drug 
utilization study, with retrospective follow up of each case 
along time, in order to detect side effect associated to 
treatment received.   
Institution: Buenos Aires Social Security Public Health 
Organization -SS.   
Period of Study: 01-01-2016 to 31-12-2016 (with a follow 
up to 31-12-2017) 
Universe of Analysis/Sample: The universe of analysis 
consists on women who have used oral pills as a 
contraceptive method, having obtained them through the 
state of Buenos Aires Social Security System (SS), during the 
period of study. All the female under program were 
considered in this research, hence sample matched the 
universe. 
Variables: age, sex, type of drug consumed, doses, drug 
consumption period, thrombotic events, co-morbidities. 
Statistical Analysis: The data were analyzed using the 
statistical program, SPSS v.17. For the analysis, the 
Kolmogórov–Smirnov test was used to know the normality of 
the variables studied. Quantitative variables were presented 
as mean values, standard deviation, and minimum and 
maximum 95% confidence interval, while those without 
normal distribution were presented in median. The 
qualitative variables were presented in percentages for each 
parameter explored. To compare means values of parametric 
variables, the Student’s t-test was used; Mann–Whitney U-
test was performed for non-parametric variables, and the 
Chi-square test was used to determine the association 
between variables. P < 0.05 was considered statistically 
significant.  
Ethical considerations: The Ethics Committee of Scientific 
Research Committee of Buenos Aires evaluated the proposal 
of the present work and considered that no ethical 
incompatibilities were detected CIC-012/16.  
RESULTS 
Buenos Aires public Social Security system covers all public 
employees and their families which constitutes 2,1 millions 
of beneficiaries. 
The Social Security holds a coverage program (called “Ser”) 
that provides to childbearing age females any type of oral 
contraception prescribed by GPs, for free (100% coverage). 
The number beneficiaries of the program using 
contraceptive pills were 69,653 women. 66,043 of them 
(94.84 %) used a combination containing new progestogen 
generation (desogestrel+ ethinylestradiol, ethinylestradiol+ 
gestodene, drospirenone+ethinylestradiol,) while 3610 
(5.18%) used either levonorgestrel or norgestrel as 
progestogen combination (estradiol-noretisterona, 
levonorgestrel+ethinylestradiol) (table 1). 
 
 
Table 1: General treatment data 
Parameter Total nº of 
beneficiaries 
nº of beneficiaries under “new” 
progestogen treatment 
combination 
nº of beneficiaries under 
“old” progestogen 
treatment combination 
Beneficiaries 69,653 66,043 3610 
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The prices of the new progestogen were in average 10.22 times more expensive than old combinations (range 2.54-17.7) (table 
2). 















3 mg 2.54 71.31 855.72 59,603,465 
desogestrel 0.150 mg 0.22 14.18 170.16 11,852,154 
gestodene 0,06  mg 0.36 10.22 122.64 8,542,244 
levonorgestrel 
Old Generation 
0,150 mg 0.17 4.88 58.56 4,078,879 
noretisterona 50 mg 0.14 4.02 48.24 3,360,060 
* In combination with ethinylestradiol except for noretisterona which is combined with estradiol.  
** Global cost per year if all beneficiaries take the combination analysed. (all prices are expressed in USD) 
DDD:  Defined daily dose 
 
With a follow up of one year, the number of young female 
that had thrombotic events (either depth vein thrombosis of 
lower limbs, thromboembolism or arterial thrombosis) were 
77 (Table 3). Of all these 77 women in oral contraception 
treatment, 75 received combinations with new progestogens 
and 2 of them used combinations with first or second 
generation progestogens.  
Even considering that the population that receives new 
combinations was 95% of all beneficiaries, adjusting these 
values to 100,000 users; the occurrences of thrombotic 
events were doubled with the consumption of 3rd and 4th 
generation progestogens (Table 3). 
 
Table 3: Thrombotic events according to progestogen consumed 
Type of 
Progestogen 
Total nº of 
beneficiaries 
nº of beneficiaries with 
thrombotic event after one year 
period treatment 
Cases of thrombosis every 
100,000 users according to type 
of progestogen  
New progestogen 
combination 
66,043 75 11.36 
Old progestogen 
combination 
3,610 2 5.54 
 
Hence, the usage of new oral contraceptives combinations 
increased in 105% the risk of thrombotic events compared 
with the old combinations that includes first and second 
generation progestogen (Table 3)   
DISCUSSION 
An oral combination contraceptive pill is an effective birth 
control method. In fact, oral contraception is an example of 
pharmacological effectiveness, with more than 99% of 
efficacy among users. It does not matter the type of 
combination, nor the progestin involve in the combination; 
the contraceptive efficacy achieved with the different 
combinations is similar18. 
Oral contraceptives are medicines with unique 
characteristics: they are always prescribed to young and 
healthy people. Combination pills are safe medications and 
the incidence of serious adverse effects is extremely rare and 
rare. However, there are severe adverse effects linked to 
thrombotic events that can put the lives at risk. The 
combination pill that involves new generation progestin has 
less androgenic effects but raise up to 3 times the risk of 
thrombosis. In our research, results show that the use of 
drosperinone, gestodene, or desogestrel was associated to a 
significant risk of thrombosis when compared with 
levonorgestrel or norgestrel2. 
It is mandatory that the public health or social security of 
countries all over the world ensure that the female 
population can fully enjoy sexual activity without the risk of 
having an unwanted pregnancy or exposing to an 
interruption of pregnancy. 
However, it is unacceptable that having scientific evidence 
about the higher risk of severe side effects associate to 
certain combinations pills, the Health systems expose their 
young and healthy population to unnecessary danger 
providing coverage for this type of medicines19. 
It cannot be argued that the decision is associated with the 
costs of the type of medication provided since, as we show in 
this paper, the costs of new generation contraceptives are up 
to 50% more expensive than those safer; without 
considering the potential costs associated with the medical 
treatment of adverse events caused by this option, which 
would rise even more those costs. 
CONCLUSSION 
This paper shows that, among the beneficiaries of the Buenos 
Aires State Social Security, the users of oral contraceptives 
that combine new generation progestin denote a greater risk 
of developing thrombosis events when compared with users 
of drugs containing levonorgestrel or norgestrel.  
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Public reproductive health policies that provide 
contraceptives to the population are crucial for the effective 
exercise of rights such as avoiding unwanted pregnancies 
and reproductive planning. However, health authorities and 
prescribers should consider significant adverse effects 
associated with some contraceptive drugs, acknowledging 
that dispensing medicines that combine estrogens with new 
generations of progestin may expose to additional and 
unnecessary levels of risks linked to thrombotic events. 
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